CTR20262075 Quadrivalent inactivated enterovirus vaccine(Sinovac Biotech) Hand, Foot and Mouth Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262075 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 22 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262075 is a hot trial to watch
Hand, Foot and Mouth Disease is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262075 is notable because it evaluates Quadrivalent inactivated enterovirus vaccine(Sinovac Biotech) in a Phase 3 design sponsored by Sinovac Biotech Co. Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262075 |
| Official title | 四价肠道病毒灭活疫苗（Vero细胞）Ⅲa期临床试验 |
| Phase / status | Phase 3 / 进行中 （尚未招募） |
| Intervention | Quadrivalent inactivated enterovirus vaccine(Sinovac Biotech) |
| Sponsor | Sinovac Biotech Co. Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 全程免疫后第15天起 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of Quadrivalent inactivated enterovirus vaccine(Sinovac Biotech) in Hand, Foot and Mouth Disease.
Allocation is 随机化, masking is 双盲, and the intervention model is 平行分组. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (全程免疫后第15天起) — 试验疫苗相较于安慰剂在6-71月龄儿童中对经RT-PCR首次确诊的由EV71、CA16、CA10和CA6中任何血清型感染引起的手足口病的保护效力
- Primary endpoint (全程免疫后第15天起) — 试验疫苗相较于安慰剂在6-71月龄儿童中对经RT-PCR首次确诊的由CA6感染引起的手足口病的保护效力
- Primary endpoint (全程免疫后第15天起) — 试验疫苗相较于安慰剂在6-71月龄儿童中对经RT-PCR首次确诊的由CA16感染引起的手足口病的保护效力
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Quadrivalent inactivated enterovirus vaccine(Sinovac Biotech) is indexed as Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status Phase 3.
Company & Deal Intelligence MCP profile: Sinovac Biotech Co. Ltd. is resolved to a normalized organization record in Beijing Shi, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262075 provides a focused lens on Hand, Foot and Mouth Disease development. Its value will be determined by whether Quadrivalent inactivated enterovirus vaccine(Sinovac Biotech) can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
